Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00073489
Status:
COMPLETED
Last Update Posted:
2011-10-17
First Post:
2003-11-21
Brief Title:
A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia CLL
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
A Pilot Trial of OSI-461 in Patients With Chronic Lymphocytic Leukemia
Status:
COMPLETED
Status Verified Date:
2011-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objectives of this study are to evaluate the safety and efficacy of OSI-461 in CLL patients
Detailed Description:
The primary objective of this study is to determine the activity of OSI-461 given twice daily orally in previously untreated CLL patients The secondary objective is to evaluate the safety profile of OSI-461 in this patient population
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None